The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 07, 2025

Filed:

Nov. 05, 2019
Applicant:

Ewha University—industry Collaboration Foundation, Seoul, KR;

Inventors:

Goo Taeg Oh, Seoul, KR;

Sejin Jeon, Seoul, KR;

Tae Kyeong Kim, Seoul, KR;

Yangsoo Jang, Seoul, KR;

Sung-Jin Hong, Seoul, KR;

Hye-Young Yun, Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); A61K 38/17 (2006.01); A61P 9/10 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 38/1709 (2013.01); A61P 9/10 (2018.01); G01N 2800/2871 (2013.01); G01N 2800/323 (2013.01); G01N 2800/324 (2013.01); G01N 2800/56 (2013.01);
Abstract

The present invention pertains to: a marker composition for diagnosing atherosclerosis severity; a composition for diagnosing atherosclerosis severity; an atherosclerosis severity diagnosis kit including the composition; a method for screening substances for preventing or treating atherosclerosis; and a method for providing information about a diagnosis of atherosclerosis severity, wherein LGI3 expression or activity levels are used. According to the present invention, the severity of atherosclerosis can be diagnosed or predicted, and personalized medicine and predictive medicine can be practiced using such information. Moreover, the present invention can treat atherosclerosis without affecting other metabolic phenotypes by administering an LGI3 antagonist.


Find Patent Forward Citations

Loading…